Effect of Histological Subtype and Treatment Modalities on T1-2 N0-1 Small Cell Lung Cancer: A Population-based Study

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2019 Apr 18

PMID 30993901

Citations 6

Authors

Seok-Whan Moon

Jong-Hee Seo

Hyun-Woo Jeon

Mi Hyoung Moon

Affiliations

Soon will be listed here.

Abstract

Background: Combined small cell lung cancer (C-SCLC) is rare and its clinical features, appropriate treatment, and prognosis are poorly understood. Reports conflict over the prognosis of C-SCLCs compared to pure small cell lung cancer.

Methods: The records of patients diagnosed with primary SCLC from 1988 to 2014 were extracted from the Surveillance, Epidemiology, and End Results database. The general features of C-SCLCs were compared to those of SCLCs. T1-2 N0-1 data was extracted and the effects of the histological subtype, treatment modality, and other prognostic factors on lung cancer-specific survival (CSS) was analyzed in a 3:1 matched dataset. Analysis was performed using the 8th edition tumor node metastasis staging system and previous staging systems adjunctively.

Results: C-SCLCs comprised 1.5% of all SCLCs (1486/98 667); 184 cases of C-SCLCs and 2681 cases of non-combined SCLCs (NC-SCLCs) were included in this study. C-SCLCs were more likely to be of a higher grade and to occur in the upper lobe than NC-SCLCs. Before matching, C-SCLCs showed better CSS (hazard ratio 0.69; P < 0.001). However, stratified Cox proportional hazards analysis in the matched dataset revealed that only treatment modality and age at diagnosis were associated with CSS; the histological subtype had no effect on survival. Of all treatment modalities, surgery with chemoradiation showed the best CSS in T1-2 N0-1 SCLC.

Conclusion: In early SCLC, surgery with chemoradiation shows the best CSS. C-SCLC patients might benefit more from multimodal treatments, including surgery, than SCLC patients.

Citing Articles

Exploring the prognostic impact of differences in treatment strategies for SCLC with different histologies and prognostic factors for C-SCLC: A SEER population-based study.

Liu J, Cao Y, Shao T, Wang Y Heliyon. 2024; 10(12):e32907.

PMID: 39015806 PMC: 11250850. DOI: 10.1016/j.heliyon.2024.e32907.

Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer.

Li Y, Wang Y, Zhou W, Chen Y, Lou Y, Qian F Thorac Cancer. 2022; 13(19):2711-2722.

PMID: 36054506 PMC: 9527167. DOI: 10.1111/1759-7714.14604.

Surgery and Surgery Approach Affect Survival of Patients With Stage I-IIA Small-Cell Lung Cancer: A Study Based SEER Database by Propensity Score Matching Analysis.

Chen X, Zhu J, Wang H, Yu W, Xu T Front Surg. 2022; 9:735102.

PMID: 35223973 PMC: 8878678. DOI: 10.3389/fsurg.2022.735102.

Prognostic factors of patients with small cell lung cancer after surgical treatment.

Zeng C, Li N, Li F, Zhang P, Wu K, Liu D Ann Transl Med. 2021; 9(14):1146.

PMID: 34430587 PMC: 8350721. DOI: 10.21037/atm-21-2912.

Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection.

Guo Y, Yang L, Liu L, Wei J, Teng F, Zhang J Thorac Cancer. 2020; 11(10):2782-2792.

PMID: 32779385 PMC: 7529571. DOI: 10.1111/1759-7714.13591.

References

Nicholson S, Beasley M, Brambilla E, Hasleton P, Colby T, Sheppard M . Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002; 26(9):1184-97. DOI: 10.1097/00000478-200209000-00009. View

Tsuchiya R, Suzuki K, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N . Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg. 2005; 129(5):977-83. DOI: 10.1016/j.jtcvs.2004.05.030. View

Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A . Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24(28):4539-44. DOI: 10.1200/JCO.2005.04.4859. View

Giroux D, Rami-Porta R, Chansky K, Crowley J, Groome P, Postmus P . The IASLC Lung Cancer Staging Project: data elements for the prospective project. J Thorac Oncol. 2009; 4(6):679-83. DOI: 10.1097/JTO.0b013e3181a52370. View

Austin P . Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28(25):3083-107. PMC: 3472075. DOI: 10.1002/sim.3697. View

Edge S, Compton C . The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6):1471-4. DOI: 10.1245/s10434-010-0985-4. View

Mountain C . Clinical biology of small cell carcinoma: relationship to surgical therapy. Semin Oncol. 1978; 5(3):272-9. View

Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M . Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol. 2011; 6(7):1229-35. DOI: 10.1097/JTO.0b013e318219aae2. View

Babakoohi S, Fu P, Yang M, Linden P, Dowlati A . Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer. 2012; 14(2):113-9. DOI: 10.1016/j.cllc.2012.07.002. View

10.

Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E . Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi99-105. DOI: 10.1093/annonc/mdt178. View

11.

Takei H, Kondo H, Miyaoka E, Asamura H, Yoshino I, Date H . Surgery for small cell lung cancer: a retrospective analysis of 243 patients from Japanese Lung Cancer Registry in 2004. J Thorac Oncol. 2014; 9(8):1140-5. DOI: 10.1097/JTO.0000000000000226. View

12.

Combs S, Hancock J, Boffa D, Decker R, Detterbeck F, Kim A . Bolstering the case for lobectomy in stages I, II, and IIIA small-cell lung cancer using the National Cancer Data Base. J Thorac Oncol. 2014; 10(2):316-23. DOI: 10.1097/JTO.0000000000000402. View

13.

Takenaka T, Takenoyama M, Inamasu E, Yoshida T, Toyokawa G, Nosaki K . Role of surgical resection for patients with limited disease-small cell lung cancer. Lung Cancer. 2015; 88(1):52-6. DOI: 10.1016/j.lungcan.2015.01.010. View

14.

Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beasley M . The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9):1243-1260. DOI: 10.1097/JTO.0000000000000630. View

15.

Zhi X, Yu J, Shi Y . Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version). Cancer. 2015; 121 Suppl 17:3165-81. DOI: 10.1002/cncr.29550. View

16.

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt W . The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11(1):39-51. DOI: 10.1016/j.jtho.2015.09.009. View

17.

Alvarado-Luna G, Morales-Espinosa D . Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res. 2016; 5(1):26-38. PMC: 4758961. DOI: 10.3978/j.issn.2218-6751.2016.01.13. View

18.

Men Y, Hui Z, Liang J, Feng Q, Chen D, Zhang H . Further understanding of an uncommon disease of combined small cell lung cancer: clinical features and prognostic factors of 114 cases. Chin J Cancer Res. 2016; 28(5):486-494. PMC: 5101222. DOI: 10.21147/j.issn.1000-9604.2016.05.03. View

19.

Zhang C, Yang H, Zhao H, Lang B, Yu X, Xiao P . Clinical outcomes of surgically resected combined small cell lung cancer: a two-institutional experience. J Thorac Dis. 2017; 9(1):151-158. PMC: 5303084. DOI: 10.21037/jtd.2017.01.07. View

20.

Zhao X, McCutcheon J, Kallakury B, Chahine J, Pratt D, Raffeld M . Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?. J Thorac Oncol. 2017; 13(2):237-245. PMC: 8057113. DOI: 10.1016/j.jtho.2017.10.010. View